Advertisement
Advertisement
NATR
Nature's Sunshine Products Inc.
24.23
USDSponsored
-0.32
-1.30%
May 08, 16:00 UTC -4
Closed
Pre-Market
24.20
-0.03
-0.12%
NATR Earnings Reports
Positive Surprise Ratio
NATR beat 13 of 18 last estimates.
72%
Next Report
Date of Next Report
Jul 29, 2026
Estimate for Q2 26 (Revenue/ EPS)
$128.67M
/$0.29
Implied change from Q1 26 (Revenue/ EPS)
+4.70%
/-3.33%
Implied change from Q2 25 (Revenue/ EPS)
+12.13%
/-17.14%
Nature's Sunshine Products Inc. earnings per share and revenue
On May 07, 2026, NATR reported earnings of 0.30 USD per share (EPS) for Q1 26, beating the estimate of 0.22 USD, resulting in a 30.72% surprise. Revenue reached 122.89 million, compared to an expected 125.18 million, with a -1.83% difference. The market reacted with a -1.30% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of 0.29 USD, with revenue projected to reach 128.67 million USD, implying an decrease of -3.33% EPS, and increase of 4.70% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Nature's Sunshine Products Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Nature's Sunshine Products Inc. reported EPS of $0.30, beating estimates by 30.72%, and revenue of $122.89M, -1.83% below expectations.
How did the market react to Nature's Sunshine Products Inc.'s Q1 2026 earnings?
The stock price moved down -1.3%, changed from $24.55 before the earnings release to $24.23 the day after.
When is Nature's Sunshine Products Inc. expected to report next?
The next earning report is scheduled for Jul 29, 2026.
What are the forecasts for Nature's Sunshine Products Inc.'s next earnings report?
Based on 4
analysts, Nature's Sunshine Products Inc. is expected to report EPS of $0.29 and revenue of $128.67M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement